Instil Bio Announces Clinical Progress In China For IMM2510/SYN-2510, A Clinical-Stage PD-L1xVEGF Bispecific Antibody
Benzinga Newsdesk 1 year ago
News
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China.
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China.